

## Galapagos

Price EUR46.83

Feedback R&amp;D day: Confidence and supportive Newsflow to come despite lack of numbers

Fair Value EUR64 (+37%)

BUY

Bloomberg	GLPG BB
Reuters	GLPG.BR
12-month High / Low (EUR)	58.5 / 32.7
Market Cap (EURm)	2,159
Ev (BG Estimates) (EURm)	0
Avg. 6m daily volume (000)	218.9
3y EPS CAGR	

	1 M	3 M	6 M	31/12/15
Absolute perf.	4.7%	15.7%	-9.3%	-17.5%
Healthcare	-1.7%	-3.0%	-7.3%	-12.4%
DJ Stoxx 600	-4.2%	-7.0%	-8.3%	-12.4%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	90.0	31.7	28.0	19.6
% change		-64.8%	-11.7%	-30.0%
EBITDA	NM	NM	NM	NM
EBIT	-36.6	-78.5	-20.4	-2.1
% change		-114.3%	74.0%	89.9%
Net income	-37.3	-13.1	30.8	45.5
% change		64.9%	NS	47.7%

	2014	2015e	2016e	2017e
Operating margin	-40.7	-247.7	-73.0	-10.5
Net margin	-41.4	-41.3	110.0	232.2
ROE	-18.1	-3.2	3.5	5.0
ROCE	-17.8	-2.8	3.1	4.2
Gearing	0.0	0.0	0.0	0.0

(EUR)	2014	2015e	2016e	2017e
EPS	-1.24	-0.34	0.81	1.19
% change	-	72.3%	NS	47.7%
P/E	NS	NS	57.9x	39.2x
FCF yield (%)	NM	NM	NM	NM
Dividends (EUR)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	0.0x	0.0x	0.0x	0.0x
EV/EBITDA	x	x	x	x
EV/EBIT	0.0x	0.0x	0.0x	0.0x

Galapagos hosted its annual R&D day which in our view highlighted the management's confidence in keeping up with its timeline for the CF program (phase II for the x3 combo towards mid-2017). While investors and us might have expected more direct comparison with Vertex' product, we acknowledge that it might be a bit early. Focus has also been put on other early/mid-stage assets and especially two developed in Osteoarthritis and IPF. Sitting on a ~EUR1bn cash pile, the future of the company will involve in and out-licensing deals to 1/ keep-up with ambitious and appreciated development plan and 2/ evolve towards an integrated biopharma company.

## ANALYSIS

- Cystic Fibrosis Program (partnered with AbbVie) well on track with confidence despite lack of numbers to fine tune our model yet.** Strategy of the management to accelerate CF program last year proven right with back-up compound being more appropriate to the development of a combination therapy. Indeed, corrector 2 back-up compound GLPG2737 has been prioritised over GLPG2665 as it features a higher lung penetration and affect less the binding of other compounds (potentiator and C1). In the heterozygote population as well as in the homozygotes F508del populations (previously communicated), early results show higher efficacy of GLPG molecules over Orkambi.


Regarding SAPHIRA phase II program for GLPG222 alone, we see slightly higher efficacy over lumacaftor. Remind that efficacy is augmented when molecules are in combination. The company has no difficulties in switching patients from Kalydeco to GLPG222. We do not rule out that Fev improvement

might be hard to see with two dose escalation in the SAPHIRA 2 trial (G551D mutation; n=30). While VRTX is faced some safety issues (deaths) with its 2<sup>nd</sup> generation corrector, GLPG did not raised any safety issues in extensive preclinical toxicity testing conducted at high dose and management mentioned the front-end loaded testing strategy pursued to minimize such effects.

Discussions with the FDA are ongoing to determine the next necessary steps to be taken ahead of opening US centers. We believe that this would be mandatory for the triple combination phase II trial. CSO, Piet Wigerinck, was confident on the ability of its team to bring the x3 combo in phase II towards mid -2017. Timeline reiterated with IND expected later this year. The CF program should be the main value creating opportunity within the next 12-18months. As a reminder, we expect a ~EUR8bn peak sales for the product which should address both F508del heterozygotes and homozygotes populations (to be put in the light of a combined USD7bn estimated peak sales for Orkambi and VX-661/VX-770).

### Triple combination in heterozygotes

G542X/F508del organoids




- Focus on early/mid-stage assets.** While the investing community has been focused on filgotinib in 2015 and should have all eyes on the CF program in 2016e/2017e, early/mid stage assets should not be overlooked. Recall that the development target that Galapagos communicated at the R&D day (i.e. one phase III program every two years alongside three PoC per year) implies a dense pipeline (...as well as in-licensing deals, cf. below).

Alongside late-stage filgotinib (phase III program to start in Q3), Galapagos management put emphasis on GLPG1972 within its inflammation portfolio. Developed in osteoarthritis (OA), this molecule showed strong efficacy on cartilage breakdown biomarkers as soon as day 14 and inhibited cartilage breakdown in healthy volunteers. Developing molecules in OA is challenging as highlighted by a high failure rate. Hence, we believe this could be a good candidate for a partnering in the US (Servier retains European rights).



## '1972 Phase 1 topline

Pharmacodynamics: cartilage breakdown biomarker in MAD



Within its Fibrosis portfolio, GLPG1690 FLORA phase II trial is on track with results expected in H1 2017 in IPF. We previously mentioned that this molecule, which features a novel mode of action (autotaxin inhibitor), could be a good partnered program too (please see our note [here](#)).

- **In and out-licensing will be key for GLPG in its goal to evolve towards an integrated biopharmaceutical company.** Out-licensing has been mentioned by management as an option, for molecules that would not fit within what should become the company's "core marketing" area i.e. Inflammation and orphan/niche fibrosis indication in our view. On the other hand, keeping up with the ambitious development targets implies in-licensing. With EUR1bn in cash and cash equivalent, GLPG should hence engage into in-licensing deals.



\* Two Ph 2a Proofs of Concept (POC) per pre-clinical candidate (PCC)

Preclinical	Ph 1	Ph 2	Ph 3	Status
Filgotinib RA				Ph 3 start: Q3 '16
Filgotinib Crohn's				Ph 3 start: Q3 '16
Filgotinib UC				Ph 2 start: Q3 '16
'1972 Osteoarthritis				Ph 1 topline: H1 '16
'2534 Atopic D				Ph 1 start: 2017

Preclinical	Ph 1	Ph 2	Status
Potentiator		'1837	Ph 2 results: H2 '16
Backup Pot. '2451			Ph 1 results: H2 '16
C1 '2222			Ph 1 results: H1 '16
BU C1 '2851			Ph 1 start: H2 '16
C2 '2737			Ph 1 start: H2 '16

Preclinical	Ph 1	Ph 2	Status
'1690 in IPF			Ph 2 results: H1 '17
'2938 in IPF			Ph 1 start: H2 '17

### VALUATION

- We reiterate our BUY rating and EUR64 fair value
- Filgotinib EUR32/share; Cash EUR21/share; CF program EUR9/share; GLPG1972+GLPG1690 EUR2/share

### NEXT CATALYSTS

- July 13<sup>th</sup>: Paris Roadshow with CFO and Dir. Business Development
- July 29<sup>th</sup>: HY results

[Click here to download document](#)



**Analyst :**  
Hugo Solvet  
33(0) 1 56 68 75 57  
hsolvet@bryangarnier.com

**Sector Team :**  
Mickael Chane Du  
Eric Le Berrigaud

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 72%

NEUTRAL ratings 0%

SELL ratings 28%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	YES
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	YES
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	YES
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Munich</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			<b>Geneva</b>
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.